Ping Xu1, Mengyang Zhao2, Zhen Liu3, Yiyi Liu2, Yiyu Chen2, Rongcheng Luo2, Weiyi Fang4. 1. Cancer Center, TCM-Integrated Hospital, Southern Medical UniversityGuangzhou, Guangdong, PR China; Peking University Shenzhen HospitalShenzhen, PR China. 2. Cancer Center, TCM-Integrated Hospital, Southern Medical University Guangzhou, Guangdong, PR China. 3. Cancer Center, TCM-Integrated Hospital, Southern Medical UniversityGuangzhou, Guangdong, PR China; Dpartment of Pathology, School of Basic Medicine, Guangzhou Medical CollegeGuangzhou, PR China. 4. Cancer Center, TCM-Integrated Hospital, Southern Medical UniversityGuangzhou, Guangdong, PR China; Cancer Research Institute, Southern Medical UniversityGuangzhou, PR China.
Abstract
PURPOSES: To examine the expression pattern of CCND1 and analyze the correlation of its nuclear expression with clinicopathologic features and prognosis in lung adenocarcinoma. METHODS: CCND1 mRNA and protein levels in lung adenocarcinoma tissues were examined. The relationship between nuclear CCND1 protein expression and clinical features including survival prognosis was analyzed. RESULTS: CCND1 mRNA levels were markedly increased in lung adenocarcinoma (P=0.0019). Western blot analysis confirmed increased nuclear CCND1 protein expression in lung adenocarcinoma specimens. Immunohistochemistry analysis confirmed that CCND1 protein was predominantly nuclear localized in lung adenocarcinoma cells and significantly elevated relative to normal lung tissues (P<0.001). Furthermore, high levels of nuclear CCND1 were positively correlated with clinical stage (P=0.026). Patients with nuclear CCND1 expression had a significantly shorter overall survival time than did patients with low expression. Interestingly, nuclear CCND1 expression in clinical stage I+II, but not clinical stage III, was shown associated with poor prognosis and shorter overall survival time for lung adenocarcinoma patients by strata analysis. Finally, nuclear CCND1 expression tended to be an independent prognostic indicator (P=0.087) for lung adenocarcinoma patient survival. CONCLUSION: Increased nuclear CCND1 is a potential unfavorable prognostic factor for lung adenocarcinoma patients, especially those with clinical early stage (stage I+II).
PURPOSES: To examine the expression pattern of CCND1 and analyze the correlation of its nuclear expression with clinicopathologic features and prognosis in lung adenocarcinoma. METHODS:CCND1 mRNA and protein levels in lung adenocarcinoma tissues were examined. The relationship between nuclear CCND1 protein expression and clinical features including survival prognosis was analyzed. RESULTS:CCND1 mRNA levels were markedly increased in lung adenocarcinoma (P=0.0019). Western blot analysis confirmed increased nuclear CCND1 protein expression in lung adenocarcinoma specimens. Immunohistochemistry analysis confirmed that CCND1 protein was predominantly nuclear localized in lung adenocarcinoma cells and significantly elevated relative to normal lung tissues (P<0.001). Furthermore, high levels of nuclear CCND1 were positively correlated with clinical stage (P=0.026). Patients with nuclear CCND1 expression had a significantly shorter overall survival time than did patients with low expression. Interestingly, nuclear CCND1 expression in clinical stage I+II, but not clinical stage III, was shown associated with poor prognosis and shorter overall survival time for lung adenocarcinomapatients by strata analysis. Finally, nuclear CCND1 expression tended to be an independent prognostic indicator (P=0.087) for lung adenocarcinomapatient survival. CONCLUSION: Increased nuclear CCND1 is a potential unfavorable prognostic factor for lung adenocarcinomapatients, especially those with clinical early stage (stage I+II).
Authors: Mi Kyoung Kim; Gwang Hun Park; Hyun Ji Eo; Hun Min Song; Jin Wook Lee; Min Ji Kwon; Jin Suk Koo; Jin Boo Jeong Journal: Fitoterapia Date: 2015-01-20 Impact factor: 2.882
Authors: Kai Bachmann; Anna Neumann; Andrea Hinsch; Michael F Nentwich; Alexander T El Gammal; Yogesh Vashist; Daniel Perez; Maximilian Bockhorn; Jakob R Izbicki; Oliver Mann Journal: J Surg Oncol Date: 2014-12-02 Impact factor: 3.454
Authors: R A Pereira; R C Ravinal; R S Costa; M S Lima; S Tucci; V F Muglia; R B dos Reis; G E B Silva Journal: Braz J Med Biol Res Date: 2014-05-02 Impact factor: 2.590